bluuebunny/crossref_metadata_2025_split huggingface dataset:
Electrical performance of a novel extravascular temporary pacing lead system
Authors: Burke M C , Doshi S , Ebner A , Husby M , Marcovecchio A , Sanghera R , Scheck D , O'connor M , Knops R E 
Published: October 2024

Abstract

Background
An investigational extravascular (EV) cardiac temporary pacing system has been developed that includes a parasternally-positioned temporary pacing lead within the anterior mediastinum. The pacing lead is inserted using a custom delivery tool through a parasternal skin incision. This novel system may provide clinical advantages over existing device alternatives that require intravascular, endocardial, or epicardial contact.

Objective
The purpose of this study was to evaluate electrical performance of an EV temporary pacing lead over 48 hours.

Methods
In this single-center study, patients who underwent a transvenous (TV) permanent pacemaker implant or replacement were simultaneously implanted with the investigational EV temporary pacing lead. Electrical performance was evaluated through analysis of capture thresholds, impedance, and R-wave amplitudes during multiple times on the day of the procedure and on the subsequent 2 days of follow-up.

Results
Lead insertions with acute capture were successful in all 8 patients (40% female, 71 ± 8 years, BMI 27 ± 3 kg/m2). Mean acute measurements for pacing capture threshold at 1.5 ms, impedance and R-wave amplitude were 6.2 mA, 1396 Ω, 5.4 mV, respectively. Pacing capture was maintained in 100% of assessments conducted over 3 days (Figure 1). There were no serious complications during insertion, removal or chronic use of the lead.

Conclusions
Results support that the investigational EV temporary pacing lead is capable of safely providing temporary pacing with thresholds typically well below the maximum output of temporary pacemakers.
Microbial specturm and antibiotic sensitivity of pocket swabs in ICD patients undergoing device replacement or lead revision surgery- findings from a ICD registry observational study
Authors: Mousavi B , Kouraki K , Strauss M , Mohammad O , Wenz A , Weisse U , Werling C , Sack F , Zahn R , Kleemann T 
Published: October 2024

Abstract

Introduction
Infection is a serious complication of implantable cardioverter defibrillator (ICD) therapy, necessitating effective preventive measures during implantation or revision surgery. The intraoperative use of antibacterial envelopes containing rifampicin and minocycline has shown promising results in reducing infection, yet, it is expensive and not cost-effective. Gentamicin sponges might be an alternative to the antibacterial envelope, however its efficacy on targeting the specific microbial spectrum found in device infection must be further investigated. Aim of the study was to identify the bacterial species obtained from pocket swabs of ICD patients undergoing revision surgery, and assess their sensitivity to gentamicin, rifampicin and minocycline.

Methods
A total of 459 intraoperative pocket swabs were collected from consecutive ICD patients who underwent elective device replacement, system upgrade or lead revision between 2017 and 6/2023. The baseline characteristics were similar in both groups (Table 1).

Results
Out of the 459 swabs analysed: 416 (90.6%) were negative for microbial growth. The remaining 43 swabs (9.4%) were tested positive for microbial growth (Table 2). Coagulase-negative- staphylococci (CoNS) were the most commonly isolated bacteria, accounting for 56% of cases. Bacteria with available antibiograms exhibited a sensitivity of 92% to gentamicin, 96% to rifampicin and 96% to Minocycline (Table 2).

Conclusion
The antibiotic sensitivity of the bacteria obtained from the pocket swabs to gentamycin, rifampicin and minocycline was similar. Thus, gentamicin sponges might be an alternative to the antibacterial envelope in patients with ICD undergoing generator replacement or revision surgery.
Extraction of old His bundle pacing leads and coronary sinus leads - an analysis of 3897 lead extraction procedures including 27 His and 253 coronary sinus lead removals
Authors: Kutarski A , Jachec W , Stefanczyk P , Dabrowski P , Glowniak A , Nowosielecka D , Tulecki L 
Published: October 2024

Abstract

Background
The lumen-less the Medtronic 3830 lead is most popular for His bundle pacing (HBP) and experience with such lead extraction are very limited especially for leads older than 4 years.

Methods
Analysis of 3898 transvenous lead extraction (TLE) procedures (including 27 HBP and 253 LVP lead extraction) was performed.

Results
The HBP was used usually in the CRT-D system (72.4%) and EF and NYHA class were better than patients with LVP extracted leads. Age of extracted HBP or LVP lead did not differ significantly (54.5 vs 50.2 months). Extraction of "old" HBP leads extraction was longer than in case of "young HBP leads (8,6 and 3.8 min). Mechanical dilatation was necessary in 63 and 100% extracted HBP leads. Unexpected procedure difficulties appeared (14,3%) and utility of second line / advanced tools had been utilised (28,6%) only when "old" HBP lead were extracted. Difficulties in extracting HBP leads were comparable to those encountered in the extraction of LVP leads of similar age. There was no extracted 3830 extracted lead break and no major complication, necessity of rescue cardiac surgery and procedure related death when HBP and LVP leads were extracted. The length of the FU period for those still alive patients was shorter for patients with removed leads for HBP as this technique was introduced significantly later than LVP. However, the 1-month mortality rate of patients with LVP lead removed is higher than in the HBP and control groups.

Conclusions
1. HBP most frequently is utilised in the CRT-D system for resynchronisation of failing heart (72.4%) 2. Extraction of HBP leads is performed most frequently due to non-infective indications (59,3%) and most often because of lead dysfunction (33,3%). 3. Extraction of "old" (&gt;40 mth) HBP leads is twice longer than younger ones (3.8 and 8,6 min) and mechanical dilatation is necessary frequently. 4. Extraction of "old" (&gt;40 mth) HBP leads is more difficult than younger ones due to appearance unexpected procedure difficulties (14,3%) and necessity utility of second line / advanced tools (28,6%) but it does not entail the risk of major complications and procedure related death. 5. Difficulties in extracting HBP leads comparable to those encountered in the extraction of LVP leads of similar age. 6. Survival after HBP and LVP lead extraction was comparable, but shorter than after removal of other leads.
Complications after cardiac implantable electronic devices in patients with severe mental illness: a Danish nationwide study
Authors: Wood-Kurland H , Storgaard Noerskov A , Nordgaard J , Porsborg Andersen M , Torp-Pedersen C , Bang C N F 
Published: October 2024

Abstract

Background
Patients with mental illness experience higher rates of postoperative complications and mortality across several types of surgery, but knowledge is lacking in relation to cardiac implantable electronic device (CIED) implantations.

Purpose
Our study aimed to investigate the 7-day, 30-day, and 90-day postoperative complication rate and mortality in patients with severe mental illness compared to the general population.

Methods
All adult patients in Denmark with a first-time pacemaker or ICD implantation during the study period from July 1995 to December 2022 were identified using the Danish nationwide registers. Severe mental illness was defined as having a preexisting diagnosis of schizophrenia and other non-affective psychotic disorders, bipolar affective disorders or major depressive disorder. Postoperative complications were obtained as diagnosis codes possibly relating to device implantation and categorized into seven types of complications: arterial thrombosis, venous thrombosis, pneumothorax, bleeding, infection, device function problem, and death. Stratified logistic regression analyses adjusted for sex and age were used to calculate the odds of postoperative complications within 7, 30, and 90 days of device implantation.

Results
Among 108,790 patients who had a de novo pacemaker or ICD implantation the mean age was 73.5 (± 12.8), 37.5% were women and 3,393 (3.1%) of the patients had preexisting severe mental illness. In total, 10,690 (9.8%) patients had one or more complications within 90 days. The number of patients with severe mental illness who experienced a complication were 407 (12.0%) while it was 10,283 (9.8%) of those without severe mental illness. Odds of death (OR 1.57, 95% CI: 1.03-2.29) were higher in patients with severe mental illness 7 days postoperatively, and 30 days postoperatively odds of venous thromboembolism (OR: 1.69, 95% CI: 1.05-2.56) and death (OR: 1.62, 95% CI: 1.29-2.01) were higher in patients with severe mental illness. 90 days postoperatively odds of venous thrombosis (OR: 1.95, 95% CI: 1.37-2.70), infection (OR: 1.45, 95% CI: 1.16-1.79), and death (OR: 1.40, 95% CI: 1.19-1.65) were higher in patients with severe mental illness compared to patients without severe mental illness, while the odds of pneumothorax were lower at all three time points for patients with severe mental illness (OR 7-days: 0.49, 95% CI: 0.21-0.95). The odds of arterial thrombosis, bleeding and device function problems were similar between the two groups at all three time points.

Conclusion
Severe mental illness was associated with increased risk of several types of complications and death following CIED implantation. This indicates that further care and attention is needed to ensure adequate treatment of patients with severe mental illness suffering from cardiac arrhythmias.Forest plot, SMI: severe mental illness
HECT domain containing-3 (HECTD3) E3 ubiquitin ligase attenuates cardiac ischemia and hypertrophy in mice
Authors: Rangrez A , Borlepawar A , Schmiedel N , Deshpande A , Helbig A , Tholey A , Mueller O J , Frank D , Frey N 
Published: October 2024

Abstract
HECT domain containing 3 (HECTD3) is one of the E3 ubiquitin ligases, the cardiac function of which is not completely understood yet. We aimed here to understand the role of HECTD3 in cardiomyocytes using loss- and gain-of-function approaches in in vitro and in vivo models.
Interestingly, we found that HECTD3 was significantly downregulated in cardiac tissue obtained from human patients suffering from cardiac hypertrophy and ischemia. We thus employed loss- and gain-of-function approaches in neonatal rat cardiomyocytes (NRVCMs) to get further insights into potential cardiac function of HECTD3. Overexpression of HECTD3 in NRVCMs attenuated cardiomyocyte hypertrophy and lipopolysaccharide (LPS) or interferon-γ (IFN- γ) induced cellular inflammation; its knockdown on the other hand aggravated these effects. Mechanistically, using Yeast two-hybrid screen, mass-spectrometry, and transcriptomics analyses, we identified Small Ubiquitin like Modifier 2 (SUMO2) Signal Transducer and Activator of Transcription-1 (STAT1) as novel substrates for HECTD3, regulation of which resulted into attenuation of hypertrophy and inflammation, respectively. To translate these in vitro results in vivo, we employed Adeno-associated virus-9 (AAV-9) mediated gene therapy approach to overexpress HECTD3 specifically in the heart of mouse models of cardiac ischemia due to permanent ligation of the left anterior descending artery (LAD), and cardiac hypertrophy due to transverse aortic constriction (TAC). Overexpression of HECTD3 in mice, though moderate but significantly improved cardiac function upon ischemic or hypertrophic stress compared to respective control groups. Importantly, in vitro findings were consistent in vivo, where AAV-9 mediated overexpression of HECTD3 substantially reduced cardiac hypertrophy and fibrosis, improved cardiac function as assessed by echocardiography, inhibited activation of STAT1-mediated downstream signaling, and attenuated infiltration of inflammatory cells to the heart after TAC or LAD ligation. This data indicates that HECTD3 is a novel modulator of cardiac ischemia, hypertrophy, and inflammation via regulation of SUMO2 and STAT1-signaling.
In conclusion, we report here a novel cardioprotective mechanism involving the E3 ubiquitin ligase HECTD3, which exerts anti-hypertrophic and anti-inflammatory effects via dual regulation of SUMO2 and its SUMOylating target STAT1. We believe that this "dual pathway" inhibition exhibits translational importance and could further be exploited for the prevention and/or therapy of heart failure due to cardiac ischemia or hypertrophy.
The essential role of the miRNA-208a/TARBP2/Sox6 axis in myosin expression in the end stage human heart failure
Authors: Kyselovic J , Cervenak Z , Hulman M , Gazova A 
Published: October 2024

Abstract
Despite diverse aetiologies, failing human hearts (HF) of various origins (coronary artery disease (CAD), dilated cardiomyopathy (DCM), restrictive cardiomyopathy, and hypertrophic cardiomyopathy (HCM)) exhibit impaired contractility and share alterations in MYH6, MYH7, and MYH7B gene expression. Here, we explore the miRNA-208a/TARBP2/Sox6 axis in regulating myosin expression within left ventricles of explanted human hearts.

Methods
Samples of left ventricles were obtained from explanted hearts of patients with terminal HF (NYHA III-IV) and reduced left ventricle ejection fraction (LVEF &lt;25%) due to CAD (n=10), DCM (n=10), HCM (n=6), and controls (n=5). We analysed the expression of cardiac myosin heavy chains (MYH6, MYH7, MYH7B), cardiac damage markers (ANP, BNP), and heart-related MyoMiRs using quantitative real-time PCR.

Results
Pre-transplant data for the 31 subjects (25 male, 3 female) included: age 54.4±8.2y, BP 112±18/67±11 mmHg, HR 79±16 min-1, LVEF 27±14%, LVEDD 8.8±15.8mm, RVEDD 32.8±5.1mm, QRS 0.140±0.05s, QT 0.42±0.04s, NT-proBNP 5551±4259 ng/l.
In all diseased groups, MYH6 mRNA was downregulated, while MYH7 and MHRT ncRNA were upregulated. We observed strong positive correlations between MYH7, MYH7B, and MHRT transcription, suggesting coordinated expression. The miRNA-208a/miRNA-208b ratio shifted heavily towards miRNA-208b in controls, with a similar effect for miRNA-499 and MYH7B. A strong negative correlation existed between miRNA-499 and MYH7B expression across HF samples. TARBP2 expression decreased slightly in all pathological groups, while Sox6 mRNA increased.

Conclusion
Elevated Sox6 expression may contribute to MYH6 downregulation and MYH7/MYH7B upregulation. Altered TARBP2 expression could promote cardiomyopathy via Sox6-mediated repression of cardiac slow-twitch myofiber proteins. Changes in miRNA-208a processing leading to Sox6 upregulation may inhibit Sox6-dependent myosin transcript expression.
Association of long-term visit-to-visit glycemic variability with risk of adverse clinical outcomes in diabetic patients with heart failure with preserved ejection fraction
Authors: Hsu J , Yang Y Y , Chuang S L , Lin T T , Huang K C , Lee J K , Wu C K , Juang J M , Lin L Y 
Published: October 2024

Abstract

Background
Previous research has linked glycemic variability (GV) with cardiovascular issues in type 2 diabetes mellitus. However, its impact on patients with heart failure with preserved ejection fraction (HFpEF) remains understudied.

Purpose
In this study, we aim to examine how glycemic variability influences on clinical cardiovascular outcomes in diabetic HFpEF patients.

Methods
We conducted a retrospective cohort analysis utilizing the electronic medical records of a tertiary medical center in Taiwan between 2014 and 2019. Diabetic patients diagnosed with HFpEF were included in the study. The coefficient of variability of fasting glucose (FGCV) was determined for each individual, and the FGCVs were categorized into tertiles. We analyzed the association between FGCV and the risks of hospitalization for heart failure (HHF), atrial fibrillation (AF), cardiac mortality, and overall mortality.

Results
A total of 74,835 patients were enrolled in this study. Among them, 753 diabetic patients with concomitant with HFpEF and measured FGCV were identified, with a median follow-up duration of 38.1 months. In the multivariable regression model, the third tertile of FGCV demonstrated a significant association with an elevated risk of HHF and overall mortality compared to the first tertile (hazard ratio [HR] 1.32, 95% confidence interval [CI] 1.03-1.50, p = 0.026; HR 1.64 [1.15-2.26], p = 0.006). Although a higher FGCV exhibited a trend towards increased AF and cardiac mortality, statistical significance was not reached (HR 1.19 [0.91-1.56], p=0.208; HR 1.64 [0.87-3.12], p=0.129). The Kaplan-Meier analyses revealed a significant association between higher FGCV and both HHF and overall mortality (log-rank p = 0.022 and &lt;0.001, respectively).

Conclusions
Our study highlights a significant association between increased GV and a higher incidence of HHF as well as an overall mortality rate in diabetic individuals with HFpEF.
Prevalent and incident anemia in PARAGON-HF
Authors: Lu H , Claggett B , Packer M , Pfeffer M A , Lam C S P , Zile M R , Desai A S , Jhund P , Lefkowitz M , Mcmurray J J V , Solomon S D , Vaduganathan M 
Published: October 2024

Abstract

Background
Anemia is a common comorbidity in patients with heart failure (HF) and is associated with adverse prognosis. Renin-angiotensin system inhibitors (RASi) have been shown to lower hemoglobin levels, potentially related to direct reductions in erythropoetin levels and hematopoiesis. We examined whether sacubitril/valsartan might attenuate this effect of RASi alone on incident anemia in patients with HF with mildly reduced or preserved ejection fraction.

Methods
PARAGON-HF was a global, multicenter randomized clinical trial of sacubitril/valsartan versus the RASi valsartan in patients with HF and left ventricular ejection fraction≥45%. Anemia was defined as hemoglobin &lt;120 g/L in women and &lt;130 g/L in men. We evaluated changes in hemoglobin, risks of incident anemia and new oral iron initiation during follow-up. We also assessed treatment effects on the primary composite endpoint of total HF hospitalizations (HFH) and cardiovascular (CV) death according to anemia status.

Results
Among 4,795 participants with a hemoglobin measurement available, 1,111 (23.2%) had anemia at randomization of which 3.5%, 77.7%, and 18.8% were characterized as micro-, normo-, and macrocytic anemia. 5.6% were treated with oral iron at baseline. Over a 2.7-year median follow-up period, patients with anemia were at nearly twice the risk of the primary outcome (21.6 vs. 11.5 per 100py; rate ratio 1.90; 95% CI: 1.62-2.21; P&lt;0.001). Compared with valsartan, sacubitril/valsartan significantly slowed the decline in hemoglobin levels by 1.4 g/L (95% CI: 0.4-2.4 g/L; P = 0.005; Figure 1 Panel A). Participants treated with sacubitril/valsartan were at significantly lower risk of developing anemia (30.3% vs. 37.6%; HR 0.76; 95% CI: 0.68-0.85; P&lt;0.001; Figure 1 Panel B) and starting oral iron therapy (8.1% vs. 10.0%; HR 0.81; 95% CI: 0.67-0.97; P = 0.026; Figure 2). Treatment effects of sacubitril/valsartan vs. valsartan on the primary endpoint were consistent among patients with and without anemia (Pinteraction=1.00).

Conclusions
Among patients with HF with mildly reduced or preserved ejection fraction, treatment with sacubitril/valsartan resulted in slower declines in hemoglobin, lower rates of incident anemia, and fewer new initiations of iron therapy compared with RASi.
Beyond conventional measures: left atrial reservoir strain as a superior prognostic marker for all-cause mortality in HFpEF
Authors: Disabato G , Attanasio A , Guida G , Camporeale A , Tondi L , Castelvecchio S , Iannotta M , Paglione G , Spagnolo P , Lombardi M , Bandera F , Guazzi M , Piepoli M 
Published: October 2024

Abstract

Background
Considerable data are available concerning improvements in diagnostic approaches over recent years for the treatment of heart failure with reduced ejection fraction (HFrEF). Conversely, regarding heart failure with preserved ejection fraction (HFpEF), there has been relatively little change in terms of therapy and prognostic stratification. Many efforts have been made to phenotype HFpEF spectrum, aiming to identify simple and reliable tools for recognizing patients at high risk for mortality.

Purpose
The aim of the present study is to identify a prognostic tool for all-cause mortality in patients with HFpEF.

Methods
From 2013 to 2024 thirty-eight HFpEF patients who underwent both transthoracic echocardiography at rest and cardiopulmonary exercise test (CPET) combined with echocardiography have been enrolled. Patients with established cardiomyopathy, such as hypertrophic cardiomyopathy and cardiac amyloidosis, have been excluded from the analysis. Mean follow-up period was 3,7 years. Primary outcome was all-cause mortality.

Results
Sixteen patients (42%) died during the study's follow-up period. No statistically significant differences were found for clinical, demographic, and therapeutic variables. Among all echocardiographic parameters, both at rest and during exertion, E/e' at rest (12 [8.9-19] vs. 17 [12-33], p-value 0.023), SPAP at rest and during exertion (31 ± 7 vs. 43 ± 16, p-value 0.021 and 51 ± 10 vs. 66 ± 17, p-value 0.019), TAPSE/SPAP at rest and during exertion (0.67 ± 0.15 vs. 0.47 ± 0.20, p-value 0.005 and 0.48 ± 0.15 vs. 0.33 ± 0.12, p-value 0.019), and left atrial reservoir function (22 [15-29] vs. 9.4 [6-15], p-value 0.001) were significantly associated with all-cause mortality (Table 1). Among CPET variables, respiratory exchange rate and oxygen pulse were associated with all-cause mortality (1.1 ± 0.13 vs. 1.18 ± 0.15, p-value 0.021 and 10 [7-11] vs. 8.1 [5.4-8.7], p-value 0.008) (Table 1). In multivariate analysis, the only independent predictor of mortality was left atrial reservoir function (p-value 0.026, OR 1.17 [1.02-1.35]). The optimal cutoff was identified using the Youden Index analysis (cut-off: 16.4%, sensitivity 85%, specificity 68%; AUC 0.839 [0.710-0.969]) (Figure 1). Survival curves based on the optimal cutoff are reported in Figure 1.

Conclusions
In a cohort of patients with HFpEF the left atrial reservoir function remains an important prognostic determinant for all-cause mortality. These results highlight the importance of estimating left ventricular filling pressures which are higher in patients diagnosed with HFPEF due to diminished ventricular compliance. Further studies with a larger cohort are needed to confirm these preliminary data.